BRISTOL-MYERS SQUIBB CO (BMY) Stock News
NYSE:BMY - New York Stock Exchange, Inc. - US1101221083 - Common Stock - Currency: USD
BMY Latest News, Press Relases and Analysis
Gapping S&P500 stocks in Monday's session
Curious about the S&P500 stocks that are gapping on Monday? Explore the gap up and gap down stocks in the S&P500 index during today's session.
Wondering what's happening in today's S&P500 pre-market session?
Let's have a look at what is happening on the US markets before the opening bell on Thursday. Below you can find the top S&P500 gainers and losers in today's pre-market session.
Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday?
Exelixis reaffirmed its 2025 sales guidance of $2.15-$2.25 billion and reported sustained long-term efficacy for Cabometyx in advanced renal cell carcinoma.
Eli Lilly Remains JPMorgan's Top Biopharma Pick For 2025, But Gilead And Bristol Myers Also Gain Praise — Is Retail On Board?
JPMorgan sees Gilead well-positioned due to its strong HIV drug portfolio and disciplined expense management.
Bristol Myers Cancer Drug Opdivo In Combination With Chemo Shows Improved Overall Survival In Certain Patients With Lung Cancer
Bristol Myers' Opdivo improved overall survival in resectable NSCLC, per final Phase 3 data. The study confirms its benefit when combined with chemotherapy.
Nuclear Power Is Solving the World’s Looming Energy Crisis
Trump’s unpredictable tariff strategy is creating major market shifts. Discover how to read his next moves and uncover hidden investment opportunities before they take off.
My “Two-Step” Plan for Surviving Shaky Markets – and Coming Out Ahead
Trump’s unpredictable tariff strategy is creating major market shifts. Discover how to read his next moves and uncover hidden investment opportunities before they take off.
Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial
How to Read Trump’s Tariff Playbook – and Prepare for His Next Moves
Trump’s unpredictable tariff strategy is creating major market shifts. Discover how to read his next moves and uncover hidden investment opportunities before they take off.
Bristol Removes DEI Pledges From Its Latest Annual Report
Last year, Bristol Myers Squibb Co. devoted half a page of its annual report to its diversity, equity and inclusion efforts, going so far as to list the the company’s internal groups for Black, Latino and LGBT employees. This year, the word “diversity” only appears under risk factors.
Earnings To Watch: Zoetis (ZTS) Reports Q4 Results Tomorrow
Animal health company Zoetis (NYSE:ZTS) will be reporting results tomorrow before market open. Here’s what to look for.
Organon (OGN) Q4 Earnings Report Preview: What To Look For
Pharmaceutical company Organon (NYSE:OGN) will be reporting earnings tomorrow before market hours. Here’s what investors should know.
MarketBeat Week in Review – 02/03 - 02/07
Despite a Monday sell-off, stocks ended the week higher, and there's evidence that sector rotation is underway; next week's read of inflation may move markets.
Weak Guidance from Bristol-Myers Could Be Creating an Opportunity
Bristol-Myers stock fell after earnings, but analysts remain bullish which suggests that any dip in the stock may create a buying opportunity
Bristol Myers Squibb (BMY) Q4 2024 Earnings Call Transcript
BMY earnings call for the period ending December 31, 2024.
Bristol Myers Squibb Tops Q4 Estimates
Bristol Myers Squibb reported strong fourth-quarter earnings but its outlook for 2025 failed to meet expectations.
Bristol-Myers Squibb Stock Slides On Weak 2025 Outlook, Retail Steps In To Buy The Dip
The company announced plans to generate $2 billion in annual cost savings by the end of 2027.
Bristol Myers Wallops Fourth-Quarter Earnings Views. But Shares Plummet 5%.
Bristol Myers Squibb stock tumbled Thursday on a light outlook for 2025 following a strong fourth-quarter report.
Bristol-Myers Squibb (NYSE:BMY) Posts Better-Than-Expected Sales In Q4 But Full-Year Sales Guidance Misses Expectations
Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced better-than-expected revenue in Q4 CY2024, with sales up 7.5% year on year to $12.34 billion. On the other hand, the company’s full-year revenue guidance of $45.5 billion at the midpoint came in 1.7% below analysts’ estimates. Its non-GAAP profit of $1.67 per share was 13.8% above analysts’ consensus estimates.
Bristol Adds to Cost Cutting With Outlook Missing Estimates
Bristol Myers Squibb Co. released sales and profit forecasts for 2025 below Wall Street’s expectations — a sign the company’s return to growth may take longer than anticipated.
